----

| ☐                                     | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---------------------------------------------|------------------------------------------------------------------------------------------------|
| OR                                          |
| ☒                                     | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934           |
| For the fiscal year ended December 31, 2018 |
| OR                                          |
| ☐                                     | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934       |
| OR                                          |
| ☐                                     | SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934    |

----

| Title of each class                                                                            |   | Name of each exchange on which registered |
|------------------------------------------------------------------------------------------------|--------|-------------------------------------------|
| American Depositary Shares, each representing 15 ordinary shares, par value NIS 0.10 per share |   | Nasdaq Capital Market                     |
| Ordinary shares, par value NIS 0.10 per share                                                  |   |  Nasdaq Capital Market*              |

----

| Large accelerated filer ☐ | Accelerated filer ☒ | Non-accelerated filer ☐ | Emerging growth company ☐ |
|---------------------------------|---------------------------|-------------------------------|---------------------------------|

----

----

| Exhibit Number  |   | Exhibit Description                                                                                                                                                                                                                                                                    |
|-----------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.1(3)          |   | Articles of Association, as amended July 5, 2017                                                                                                                                                                                                                                       |
| 2.2(2)          |   | Deposit Agreement dated as of July 21, 2011 among the Registrant, The Bank of New York Mellon, as Depositary, and                all Owners and Holders from time to time of American Depositary Shares issued thereunder                                                              |
| 2.3(2)          |   | Form of American Depositary Receipt; the Form is Exhibit A of the deposit agreement which is Exhibit 2.2 above.                                                                                                                                                                        |
| 4.5(10)         |   | Employment Agreement with Philip Serlin, dated May 24, 2009, as amended                                                                                                                                                                                                                |
| 4.16†(1)  |   | License Agreement entered into as of November 25, 2007 between BioLine Innovations Jerusalem                L.P. and Innovative Pharmaceutical Concepts, Inc.                                                                                                                          |
| 4.18(9)         |   | BioLineRx Ltd. Amended and Restated 2003 Share Incentive Plan                                                                                                                                                                                                                          |
| 4.33(4)         |   | License Agreement entered into as of September 2, 2012 by and between the Registrant and Biokine                Therapeutics Ltd.                                                                                                                                                      |
| 4.34(5)†  |   | Amendment Agreement entered into as of October 2, 2018 by and between the Registrant and Biokine                Therapeutics Ltd.                                                                                                                                                      |
| 4.35(5)         |   | Loan Agreement entered into as of October 2, 2018, by and between the Registrant and Kreos                Capital V (Expert Fund) L.P.                                                                                                                                                 |
| 4.36(6)         |   | Compensation Policy for Executives and Directors                                                                                                                                                                                                                                       |
| 4.37(7)         |   | Lease Agreement entered into as of August 7, 2014 between S.M.L. Solomon Industrial Buildings                Ltd. and Infrastructure Management and Development Established by C.P.M. Ltd. as Lessor and the Registrant as Lessee, as amended (English summary of the Hebrew original) |
| 4.38(7)†  |   | Investment and Collaboration Agreement entered into as of December 16, 2014 between the                Registrant and Novartis Pharma AG                                                                                                                                               |
| 4.39(8)†  |   | License Agreement entered into as of December 22, 2014 between the Registrant and Wartner Europe BV                                                                                                                                                                                    |
| 4.40(4)†  |   | Clinical Trial Collaboration and Supply Agreement entered into as of January 11, 2016 between the                Registrant and Merck Sharp & Dohme B.V.                                                                                                                           |
| 4.41†*    |   | Amendment No. 2 to Clinical Trial Collaboration and Supply Agreement entered into as of July 24,                2018 between the Registrant and Merck Sharp & Dohme B.V.                                                                                                           |
| 4.42(10)† |   | Combination Study Agreement entered into as of September 6, 2016 between the Registrant and                Genentech, Inc.                                                                                                                                                             |
| 4.43(10)        |   | Employment Agreement with Mali Zeevi, dated September 16, 2009, as amended                                                                                                                                                                                                             |

----

| Exhibit Number  |   | Exhibit Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.44(10)        |   | Employment Agreement with Abi Vainstein-Haras, dated April 2, 2014, as amended Exhibit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 4.45(10)        |   | Employment Agreement with Ella Sorani, dated January 11, 2017                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 4.46(10)† |   | Amended and Restated Exclusive License Agreement entered into as of April 30, 2013 between the University of                Massachusetts and Agalimmune Ltd.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 4.47†*    |   | Patent and Know-how License Agreement entered into as of September 19, 2017                between Kode Biotech Limited and Agalimmune Ltd.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 4.49†*    |   | Second Amendment Agreement entered into as of October 16, 2018 between the University of                Massachusetts and Agalimmune Ltd.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 4.50†*    |   | Amendment No. 1 to License Agreement entered into as of June 18, 2018 between the Registrant and                Wartner Europe BV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 12.1**          |   | Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 12.2**          |   | Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 13.1*           |   | Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350,                as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 13.2*           |   | Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant                to Section 906 of the Sarbanes-Oxley Act of 2002                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 15.5*           |   | Consent of Kesselman & Kesselman, Certified Public Accountant (Isr.), a member of PricewaterhouseCoopers                International Limited, independent registered public accounting firm for the Registrant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 15.8(11)        |   | Subscription Agreement entered into as of July 26, 2017 among the Registrant and Biotechnology                Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., Investment 10, LLC and MSI BVF SPV, L.L.C. (the “BVF Investors”)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 15.9(11)        |   | Form of Series A Warrant issued to the BVF Investors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 15.10(11)       |   | Form of Series B Warrant issued to the BVF Investors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 15.11(11)       |   | Voting and Standstill Agreement entered into as of July 26, 2017 among the Registrant and the BVF                Investors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 15.12(12)       |   | At-the-market Sales Agreement entered into October 30, 2017, between the Registrant and BTIG, LLC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 101*            |   | The following financial information from BioLineRx Ltd.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2017 formatted in XBRL (Extensible Business Reporting Language):              (i) Consolidated Statements of Financial Position at December 31, 2017 and 2016; (ii) Consolidated Statements of Comprehensive Loss for the years ended December 31, 2017, 2016 and 2015; (iii) Statements of Changes in Equity for the years              ended December 31, 2017, 2016 and 2015; (iv) Consolidated Cash Flow Statements for the years ended December 31, 2017, 2016 and 2015; and (v) Notes to the Consolidated Financial Statements. Users of this data are advised, in accordance with              Rule 406T of Regulation S-T promulgated by the SEC, that this Interactive Data File is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for              purposes of Section 18 of the Exchange Act, and otherwise is not subject to liability under these sections. |

----

----

|   | BIOLINERX LTD.By: /s/ Philip A. Serlin                           Philip A. Serlin       Chief Executive Officer |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----